Compare BioNano Genomics Inc (BNGO) vs Dollar Tree, Inc. (DLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Dollar Tree, Inc. — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.20M), while Dollar Tree, Inc. trades at $127.06 (market cap $23.94B). The key difference: Dollar Tree, Inc. is far larger — about 1813.6× BioNano Genomics Inc's market cap, and Dollar Tree, Inc. is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | DLTR | |
|---|---|---|
Market Cap | $13.20M | $23.94B |
Sector | Health | Health |
52-Week High | $4.92 | $141.21 |
52-Week Low | $1.09 | $85.04 |
Enterprise Value | $15.81M | $30.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Dollar Tree (DLTR) trades at $126.38, up 1.18% today, with a bullish technical signal and strong recent earnings beats. The company's fundamentals show a net loss in 2025 but improving cash flow and a $2.5 billion share repurchase authorization signal confidence. Analyst consensus is a Buy with a $131 price target, though valuation ratios like P/E of 20.29 and P/B of 6.93 reflect moderate pricing.
The outlook is positive due to earnings momentum and cost controls, but risks include traffic softness and tariff pressures. Upside potential exists if margin gains and multi-price strategy sustain growth, yet investors must weigh high debt and competitive headwinds against cash flow strength and institutional support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Dollar Tree, Inc.
Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →
